Streptococcus pneumoniae in vitro development of resistance to amoxicillin/clavulanic acid, cefaclor, levofloxacin and azithromycin

被引：7

作者：

Koeth, LM

Good, CE

Saunders, KA

Jakielaszek, C

机构：

[1] Lab Specialists Inc, Westlake, OH 44145 USA

[2] GlaxoSmithKline, Collegeville, PA USA

[3] Univ Hosp Cleveland, Cleveland, OH 44106 USA

来源：

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS | 2004年 / 24卷 / 02期

关键词：

amoxicillin/clavulanic acid; resistance development; Streptococcus pneumoniae;

D O I：

10.1016/j.ijantimicag.2003.12.016

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

The purpose of this study was to determine effect of repeated exposure to sub-inhibitory concentrations of amoxicillin/clavulanic acid on the development of resistance in Streptococcus pneumoniae. Other agents, azithromycin, cefaclor and levofloxacin, were also tested. Twenty S. pneumoniae were passaged for 9 days in the presence of sub-inhibitory concentrations of each antimicrobial agent and MICs determined by NCCLS macro-dilution method. There was a four-fold increase in amoxicillin/clavulanic acid MICs for 2 of 20 isolates. Three of 9 tested against cefaclor, 11 of 13 tested against azithromycin and 9 of 20 tested against levofloxacin showed greater than or equal to4-fold increase. Amoxicillin/clavulanic acid was the most stable of the agents tested. Cefaclor MICs were also fairly stable. Azithromycin and levofloxacin MICs were most affected. (C) 2004 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

引用

收藏

页码：144 / 149

页数：6

相关论文

共 18 条

[1]

[Anonymous], 2002, M100S12 NCCLS

[2] Brief report: Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. [J].

Davidson, R ;

Cavalcanti, R ;

Brunton, JL ;

Bast, DJ ;

de Azavedo, JCS ;

Kibsey, P ;

Fleming, C ;

Low, DE .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (10) :747-750

[3] In vitro development of resistance to five quinolones and amoxicillin-clavulanate in Streptococcus pneumoniae [J].

Davies, TA ;

Pankuch, GA ;

Dewasse, BE ;

Jacobs, MR ;

Appelbaum, PC .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (05) :1177-1182

[4] Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995 [J].

Doern, GV ;

Heilmann, KP ;

Huynh, HK ;

Rhomberg, PR ;

Coffman, SL ;

Brueggemann, AB .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (06) :1721-1729

[5] Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999 [J].

Hoban, DJ ;

Doern, GV ;

Fluit, AC ;

Roussel-Delvallez, M ;

Jones, RN .

CLINICAL INFECTIOUS DISEASES, 2001, 32 :S81-S93

[6]

Jacobs MR, 1999, AM J MANAG CARE, V5, pS651

[7] High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA [J].

Janoir, C ;

Zeller, V ;

Kitzis, MD ;

Moreau, NJ ;

Gutmann, L .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (12) :2760-2764

[8] Prevalence and characterization of the mechanisms of macrolide, lincosamide, and streptogramin resistance in isolates of Streptococcus pneumoniae [J].

Johnston, NJ ;

De Azavedo, JC ;

Kellner, JD ;

Low, DE .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (09) :2425-2426

[9] In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: Data from the SENTRY antimicrobial surveillance program [J].

Jones, RN ;

Pfaller, MA .

CLINICAL INFECTIOUS DISEASES, 2000, 31 :S16-S23

[10] Comparative in vitro activity of gemifloxacin to other fluoroquinolones and non-quinolone agents against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the United States in 1999-2000 [J].

Koeth, LM ;

Jacobs, MR ;

Bajaksouzian, S ;

Zilles, A ;

Lin, GR ;

Appelbaum, PC .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2002, 19 (01) :33-37